作者
Wenfeng Fang, Yuxiang Ma, Jiani C Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang, Yan Huang, Hongyun Zhao, Yang W Shao, Li Zhang
发表日期
2019/8/15
期刊
Clinical Cancer Research
卷号
25
期号
16
页码范围
5015-5026
出版商
American Association for Cancer Research
简介
Purpose
Immune checkpoint inhibitors (ICI) have revolutionized cancer management. However, molecular determinants of response to ICIs remain incompletely understood.
Experimental Design
We performed genomic profiling of 78 patients with non–small cell lung cancer (NSCLC) who underwent anti–PD-(L)1 therapies by both whole-exome and targeted next-generation sequencing (a 422-cancer-gene panel) to explore the predictive biomarkers of ICI response. Tumor mutation burden (TMB), and specific somatic mutations and copy-number alterations (CNA) were evaluated for their associations with immunotherapy response.
Results
We confirmed that high TMB was associated with improved clinical outcomes, and TMB quantified by gene panel strongly correlated with WES results (Spearman's ρ = 0.81). Compared with wild-type, patients with FAT1 …
学术搜索中的文章
W Fang, Y Ma, JC Yin, S Hong, H Zhou, A Wang… - Clinical Cancer Research, 2019